Press Release-InxMed

About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Home page

2026-09

InxMed and Chugai Enter into a Worldwide License Agreement for　SPYK04, a RAF-MEK Molecular Glue

HONG KONG and TOKYO, September 29, 2026 -- InxMed (Hong Kong) Limited (hereafter “InxMed”) and Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, hereafter “Chugai”) today announced that they have entered into a worldwide license agreement regarding SPYK04, a RAF-MEK molecular glue discovered by Chugai for the treatment of solid tumors.

2026-08

InxMed Announces Publication in The Lancet Oncology Featuring Encouraging Antitumor Activity of Ifebemtinib in Combination with Garsorasib in Previously Treated Metastatic Colorectal Cancer (CRC) Harboring KRAS G12C Mutation

NANJING, China, August 28, 2026, -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRAS G12C inhibitor, in previously treated KRAS G12C-mutant metastatic colorectal cancer (CRC), have been published online in The Lancet Oncology.

2026-08

Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial

Zhengbo Song, Liming Zhu, Ying Liu, Rongbo Lin, Xingya Li, Yongzhong Luo, Yuan Yuan, Huaqiu Shi, Yiping Zhang, Baoyuan Zhang, Yinxin Zhu, Zaiqi Wang, Xiangdong Chen.Lancet Oncol. 2026 Sep;27(9):1133-1145.

2026-07

InxMed Announces Publication in The Lancet Respiratory Medicine Featuring Promising Anticancer Activity of Ifebemtinib in combination with Garsorasib in First-Line non-small cell lung cancer (NSCLC) Harboring KRASG12C Mutation

NANJING, China, July 9, 2026 /PRNewswire/ -- InxMed Co., Ltd ("InxMed"), a clinical-stage biotechnology company dedicated to developing innovative therapies targeting cancer treatment resistance and metastasis, today announced that the clinical results of ifebemtinib (IN10018), a highly selective focal adhesion kinase (FAK) inhibitor, in combination with garsorasib (D-1553), a potent KRASG12C inhibitor in first-line KRASG12C-mutant NSCLC, have been published online in The Lancet Respiratory Medicine.

2026-07

Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 tria

Zhengbo Song, Xingya Li, Rongbo Lin, Huaqiu Shi, Yuan Yuan, Ying Liu, Yongzhong Luo, Tangfeng Lv, Yiping Zhang, Liming Zhu, Yinxin Zhu, Ling Zhang, Zaiqi Wang.Lancet Respir Med. 2026 Sep;14(9):775-785.

2026-01

Aug，2025

Received the third Breakthrough Therapy Designation by China NMPA for 2L+ CRC with KRAS G12C Mutation

< 1 2 3 4...12 > proceed page

QUICK LINKS

About Us
- Overview
- History
- Mission
- Team
- Contact Us
Our Science
- Our FoCus
- Our Publications
Pipeline
Partnerships
Press Release
- Press Release
- Media Coverage
Join Us
Legal Notice
Privacy Policy

Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

MESSAGE

SEO